HPV-Based Cervical Cancer Screening at the Point-of-Care? A Preclinical Evaluation of the Pluslife HPV 16/18/45 Assay
Preprints.org
Abstract
Background: Human papillomavirus (HPV) nucleic acid-based testing is the preferred method for cervical cancer screening. Leveraging point-of-care (POC) technologies can increase accessibility to screening in resource-limited settings.
- Pluslife HPV-16/18/45 nucleic acid test card
- Cervical cancer
- HPV 16/18/45
- Assay performance agreement
- Humans
The paper
Noble L, Scott L, Gast D et al.
Preprints.org · 9 Sep 2026 · CC BY · Preprint, not peer-reviewed
